Printer Friendly

Novartis Pharma, Chugai Pharmaceutical to Ship Agent for Postmenopausal Breast Cancer.

Tokyo, Japan, May 11, 2006 - (JCN) - On May 10, Novartis Pharma and Chugai Pharmaceutical jointly announced that they will release Femara Tablet 2.5mg (letrozole), an agent for the treatment of postmenopausal breast cancer, on May 11.

The new agent is available for adjuvant treatment of early-stage breast cancer in postmenopausal women as well as primary and secondary care for patients with advanced and recurrent breast cancer.

Femara is currently available in over 90 countries worldwide.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:May 11, 2006
Words:86
Previous Article:Kissei Pharmaceutical, Daiichi Pharmaceutical Jointly Launch Urination Disorder Improving Drug.
Next Article:Eisai, Nitto Denko to Co-develop Transdermal Formulation of Alzheimer's Disease Agent ARICEPT.


Related Articles
Drug cuts recurrence of breast cancer.
National Institute of Technology and Evaluation, Astellas Pharma, Chugai Pharmaceutical to Collaborate in Searching Microorganisms in Vietnam.
Chugai Pharmaceutical to Spin off Production Operations.
Novartis Pharma to Market Femara, Ethical Agent for Postmenopausal Breast Cancer, in Japan.
Breast cancer & weight.
Chugai Pharmaceutical to Establish an Oncology Unit.
Novartis and Mochida Pharmaceutical to Co-promote Diovan in Japan.
Anti-Cancer Agent Avastin(R) Approved in Japan.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |